Expert Review of Vaccines最新文献_第2页

Breaking the cycle: considerations for a life-course vaccination strategy against varicella-zoster virus. 打破循环：对水痘-带状疱疹病毒终身疫苗接种战略的考虑。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-19 DOI: 10.1080/14760584.2025.2514527

Giacomo Casabona, Paolo Bonanni, Giovanni Gabutti, Volker Vetter, Maurine Duchenne, Raunak Parikh

{"title":"Breaking the cycle: considerations for a life-course vaccination strategy against varicella-zoster virus.","authors":"Giacomo Casabona, Paolo Bonanni, Giovanni Gabutti, Volker Vetter, Maurine Duchenne, Raunak Parikh","doi":"10.1080/14760584.2025.2514527","DOIUrl":"10.1080/14760584.2025.2514527","url":null,"abstract":"Introduction: Varicella-zoster virus (VZV) is a highly contagious virus that manifests as varicella (chickenpox) as primary infection and reactivates as herpes zoster (HZ, shingles), with the potential for severe complications. Vaccines against varicella and HZ are available and highly effective, but recommendations vary between countries.Areas covered: This qualitative review discusses the literature regarding (i) the burden of varicella and HZ; (ii) current approaches to vaccination against VZV-related diseases and reasons why varicella and HZ vaccination may not have been widely implemented, and (iii) real-world evidence and trends from countries with vaccination program experience.Expert opinion: Varicella and HZ pose significant burdens. The availability of effective vaccines with established safety profiles means that prevention of both manifestations of VZV disease is now largely possible. Reasons why National Immunization Technical Advisory Groups may not recommend varicella and HZ vaccination programs include cost-effectiveness, considerations relating to the interplay of both diseases, and low awareness of the true disease burden. Nevertheless, real-world evidence from countries with existing vaccination programs is demonstrating positive impacts of vaccination on disease incidence and cost. Including both varicella and HZ vaccines in National Immunization Programs can be an effective life-course strategy to tackle the burden of VZV-related diseases.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"556-569"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between parental vaccine literacy and their willingness to vaccinate children against influenza in china. 中国父母疫苗素养与儿童接种流感疫苗意愿的关系

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-14 DOI: 10.1080/14760584.2025.2534617

Zhuoran Huang, Ziwen Song, Minjuan Shi, Zhiheng Liao, Lisha Deng, Hongbiao Chen, Jianhui Yuan, Caijun Sun

{"title":"Relationship between parental vaccine literacy and their willingness to vaccinate children against influenza in china.","authors":"Zhuoran Huang, Ziwen Song, Minjuan Shi, Zhiheng Liao, Lisha Deng, Hongbiao Chen, Jianhui Yuan, Caijun Sun","doi":"10.1080/14760584.2025.2534617","DOIUrl":"10.1080/14760584.2025.2534617","url":null,"abstract":"Background: Influenza poses a significant global public health burden, particularly among pediatric populations. However, the coverage of influenza vaccination among Chinese children remains inadequate.Research design and methods: This study explores the relationship between parental vaccine literacy and willingness to vaccinate their children against influenza. A cross-sectional online survey was conducted using an anonymous questionnaire. Vaccine literacy was measured by the Vaccine Health Literacy scale, and logistic regression with mediation analyses was used to identify influencing factors.Results: Among 6,177 participants, 94.67% expressed willingness to vaccinate their children. Higher vaccine literacy, especially interactive vaccine literacy, was positively associated with willingness and mediated key predictors. Male parents (OR = 1.408, p = 0.034) with prior vaccination history (OR = 6.402, p < 0.001) were more likely to vaccinate, while those with younger age (OR = 0.959, p < 0.001) and lower education (OR = 0.587, p < 0.001) were less likely to vaccinate.Conclusions: Our study found that parents' vaccine literacy, particularly interactive vaccine literacy, shows a potential association with their willingness to vaccinate their children against influenza. Targeted interventions aimed at improving parental vaccine literacy and addressing their vaccine hesitancy are critical for enhancing influenza vaccination coverage among children.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"612-622"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America. 无细胞免疫对百日咳的影响北美洲、中美洲和南美洲四个国家的比较经验。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-08-29 DOI: 10.1080/14760584.2025.2550973

María L Avila-Aguero, Miguel Betancourt-Cravioto, Ruby Trejo Varon, Juan Pablo Torres, Ana G Lucas, Francisco Becerra-Posada, Carlos Espinal

引用次数: 0

Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season. 美国60岁及以上成年人RSV疫苗接种对公共卫生的影响，使用来自最初引入后季节的真实证据

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-08-04 DOI: 10.1080/14760584.2025.2539893

Frederik Verelst, David Singer, Jonathan Graham, Mei Grace, Elizabeth M La, Eliana Biundo

{"title":"Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season.","authors":"Frederik Verelst, David Singer, Jonathan Graham, Mei Grace, Elizabeth M La, Eliana Biundo","doi":"10.1080/14760584.2025.2539893","DOIUrl":"10.1080/14760584.2025.2539893","url":null,"abstract":"Background: Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with certain health conditions. Adjuvanted RSVPreF3 and non-adjuvanted RSVpreF vaccines were approved in 2023 for use in adults aged ≥60 years in the United States (US). This study explored the impact of RSV vaccination during the first season of vaccine availability.Research design and methods: A Markov model was adapted to compare RSV-related outcomes in adults aged ≥60 years with or without RSV vaccination. Analyses were based on real-world RSV vaccination uptake and effectiveness in the 2023-2024 season. Scenario analyses assumed the same higher uptake as for influenza vaccines.Results: Over 1 year, real-world RSV vaccinations were estimated to avert 18,326 RSV-related emergency department (ED) visits, 23,630 hospitalizations, and 1,930 deaths versus no vaccination. Assuming the same uptake as for influenza vaccines resulted in considerable additional RSV disease burden averted (avoiding a total of 65,740 RSV-related ED visits, 84,551 hospitalizations, and 6,838 deaths over 1 year vs. no vaccination).Conclusions: Findings suggest that real-world RSV vaccinations have substantially reduced RSV disease burden in the US. Increasing RSV vaccination uptake among eligible adults aged ≥60 years could provide additional public health benefits.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"797-806"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global variations in immunisation strategies against pertussis in infancy. 婴儿百日咳免疫策略的全球差异。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-09-22 DOI: 10.1080/14760584.2025.2562197

Sarah Murphy, Anna Kelly, Dominic F Kelly

{"title":"Global variations in immunisation strategies against pertussis in infancy.","authors":"Sarah Murphy, Anna Kelly, Dominic F Kelly","doi":"10.1080/14760584.2025.2562197","DOIUrl":"10.1080/14760584.2025.2562197","url":null,"abstract":"Introduction: The World Health Organisation (WHO) introduced the Expanded Programme on Immunisation (EPI) in 1974 to reduce morbidity and mortality from a range of vaccine-preventable infectious diseases including pertussis. However, almost 50 years later pertussis infection continues to be a public-health concern in high- and low-and-middle-income countries.Areas covered: We review: the clinical heterogeneity of disease in an immunized population and the current estimates of global disease burden; the vaccine-types currently used to prevent pertussis infection and the evidence behind the current schedules of immunization recommended by the WHO; the current understanding of the immune responses relating to protection from disease and colonization; the regional differences in routinely used schedules of immunization.Expert opinion: The current heterogeneity of schedules and vaccines reflects uncertainty about the best strategies for long-term control of pertussis infection. Whole cell pertussis vaccines are associated with sustained population control of infection but are reactogenic; acellular pertussis vaccines are less reactogenic but do not appear to give sustained protection against transmission. Continuing to develop and apply emerging insights into the nature of the immune responses needed to provide robust protection against pertussis may enable the development of novel vaccines and optimal schedules of immunization.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"882-903"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE? 欧洲消除宫颈癌和预防人乳头瘤病毒（hpv）相关癌症的准备情况评估——我们是否赢得了竞赛？

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-15 DOI: 10.1080/14760584.2024.2438759

Eugenia Karamousouli, Ugne Sabale, Stefano Valente, Fanut Morosan, Maria Heuser, Olivia Dodd, Danielle Riley, Louise Heron, Giovanna Elisa Calabrò, Theodoros Agorastos, Paul Sevelda, Zoárd Tibor Krasznai, Shay Nahum, Rune Horby

{"title":"Readiness assessment for cervical cancer elimination and prevention of human papillomavirus (HPV)-related cancers in Europe - are we winning the RACE?","authors":"Eugenia Karamousouli, Ugne Sabale, Stefano Valente, Fanut Morosan, Maria Heuser, Olivia Dodd, Danielle Riley, Louise Heron, Giovanna Elisa Calabrò, Theodoros Agorastos, Paul Sevelda, Zoárd Tibor Krasznai, Shay Nahum, Rune Horby","doi":"10.1080/14760584.2024.2438759","DOIUrl":"10.1080/14760584.2024.2438759","url":null,"abstract":"Introduction: To address the cervical cancer burden globally, the World Health Organization and European Union released strategies to facilitate HPV-related cancers prevention, including cervical cancer elimination. This research assessed European country level readiness to achieve cervical cancer elimination by adhering to such strategies.Areas covered: Readiness for cervical cancer elimination was assessed across a range of guiding questions relevant to three defined key domains: vaccination, screening, and treatment, each with two sub-domains focusing on decision making and implementation efforts. Publicly available data sources were used to inform the scoring across domains, to tier countries into either high, moderate-high, moderate-low, and low readiness archetypes.Key parameters identified associated with the high readiness archetype were high vaccination coverage rates (>70%), availability of gender neutral and catch-up vaccination, school-based vaccination availability, organized screening programs, use of HPV DNA primary screening tests, and data surveillance.Expert opinion: Our analysis highlights significant variability in decision making and implementation of vaccination, screening, and treatment programmes across Europe. Country scores expose the need for a multifaceted approach to achieve cervical cancer elimination in Europe, encompassing solid decision making commitments, implementation of these commitments, and the ability to collect, surveil, and apply the data use accurately.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"11-26"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants. 二价蛋白COVID-19疫苗SCTV01C对抗原匹配和不匹配变体的持续免疫原性

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/14760584.2025.2456231

Guiqiang Wang, Kexin Zhao, Xiuli Zhao, Yimin Cui, Peng He, Tianzuo Zhang, Yanchao Wang, Rui Shi, Yanhua Li, Qian Wang, Yanping Ren, Zhisong Chen, Xuedan Zhao, Zekang Xie, Yufei Liang, Qingyun Tian, Jing Pan, Chao Zhang, Ying Han, Yuyang Dai, Siyang Ni, Yun Zhang, Xinjie Yang, Yongpan Fu, Dongfang Liu, Jing Li, Miaomiao Zhang, Zhongyu Hu, Liangzhi Xie

{"title":"Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants.","authors":"Guiqiang Wang, Kexin Zhao, Xiuli Zhao, Yimin Cui, Peng He, Tianzuo Zhang, Yanchao Wang, Rui Shi, Yanhua Li, Qian Wang, Yanping Ren, Zhisong Chen, Xuedan Zhao, Zekang Xie, Yufei Liang, Qingyun Tian, Jing Pan, Chao Zhang, Ying Han, Yuyang Dai, Siyang Ni, Yun Zhang, Xinjie Yang, Yongpan Fu, Dongfang Liu, Jing Li, Miaomiao Zhang, Zhongyu Hu, Liangzhi Xie","doi":"10.1080/14760584.2025.2456231","DOIUrl":"10.1080/14760584.2025.2456231","url":null,"abstract":"Background: The development of bivalent or multivalent vaccines offers a promising strategy for combating SARS-CoV-2 mutations.Research design and methods: In this phase 2 trial, conducted from 1 December 2021, to 25 July 2023, 392 unvaccinated adults aged ≥18 years were randomized to receive a primary series of two doses and a booster dose of SCTV01C, a bivalent protein SARS-CoV-2 vaccine.Results: Geometric mean titers (GMTs) of neutralizing antibodies (nAb) against live Alpha, Beta, Delta, and Omicron showed 85.4-, 100.0-, 32.1-, and 9.8-fold increase from baseline on 28 days, and 49.4-, 55.3-, 5.7-fold increase against live Alpha, Beta, and Omicron on 90 days after primary series. At Day 28 and Day 90 following the booster dose, GMTs of nAb against Beta, BA.2 and BA.5 variants showed 12.1- and 8.8-, 13.8- and 7.1-, 18.7-, and 11.9-fold of increase from baseline, respectively. Reactogenicity was generally mild, with one adverse event of special interest (AESI) and 9 ≥Grade 3 treatment-related adverse events (TRAEs); all recovered within 3 days.Conclusions: SCTV01C, when administered as both a primary series and a booster vaccination, exhibited encouraging sustained immunogenicity against both antigen-matched and antigen-mismatched variants, with no significant safety concerns.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05148091.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"128-137"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing influenza vaccination uptake: a systematic review and meta-analysis of intervention strategies. 加强流感疫苗接种：干预策略的系统回顾和荟萃分析。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-08-23 DOI: 10.1080/14760584.2025.2550986

YuNing Wang, YaZhen Zhang, JiaYu Wang, NaiYang Shi, HuaJie Jin, Hui Jin

{"title":"Enhancing influenza vaccination uptake: a systematic review and meta-analysis of intervention strategies.","authors":"YuNing Wang, YaZhen Zhang, JiaYu Wang, NaiYang Shi, HuaJie Jin, Hui Jin","doi":"10.1080/14760584.2025.2550986","DOIUrl":"https://doi.org/10.1080/14760584.2025.2550986","url":null,"abstract":"Introduction: Despite extensive efforts, global influenza vaccination rates remain suboptimal, particularly among high-risk populations.Research design and methods: We conducted a comprehensive literature search up to April 2023. Experimental studies assessing the effectiveness of interventions on influenza vaccination uptake were included, expressed as risk ratios (RR) with 95% confidence intervals (CI). Random-effects meta-analysis models were utilized for pooled estimates, with heterogeneity assessed through I2. Subgroup analyses and meta-regressions were performed.Results: This meta-analysis includes 180 studies involving 2,390,119 participants and comprehensively evaluates the effectiveness of recipient-, provider-, health system-based, and multitarget interventions. Overall, interventions significantly increased vaccination rates, with a pooled RR of 1.26 (95% CI, 1.21 to 1.32). Notably, provider-based interventions were more effective for healthcare workers (RR = 1.56; 95% CI, 1.46 to 1.66), whereas recipient-based interventions were more efficacious for pregnant women (RR = 1.42; 95% CI, 1.09 to 1.85). Multitarget strategies were the most effective among older adults (RR = 2.10; 95% CI, 1.61 to 2.72) and population under age of 18 (RR = 1.53; 95% CI, 1.23 to 1.90).Conclusions: These findings provide critical insights for optimizing public health strategies, underscoring the need for innovative and tailored approaches to enhance global vaccination uptake.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"17-27"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response. 迈向丙型肝炎疫苗：引发有效b细胞反应的免疫策略概述。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-01-28 DOI: 10.1080/14760584.2025.2452955

Gabriel L Costa, Giuseppe A Sautto

{"title":"Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response.","authors":"Gabriel L Costa, Giuseppe A Sautto","doi":"10.1080/14760584.2025.2452955","DOIUrl":"10.1080/14760584.2025.2452955","url":null,"abstract":"Introduction: Fifty-eight million people worldwide are chronically infected with hepatitis C virus (HCV) and are at risk of developing cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antivirals are highly effective; however, they are burdened by high costs and the unchanged risk of HCC and reinfection, making prophylactic countermeasures an urgent medical need. HCV high genetic diversity is one of the main obstacles to vaccine development. The protective role of the humoral response directed against the HCV E2 glycoprotein is well established, and broadly neutralizing antibodies play a crucial role in effective viral clearance.Areas covered: This review explores the HCV targets and the different vaccination approaches, encompassing different expression systems, antigen selection strategies, and delivery methods, focusing on those aimed at eliciting a broad and effective humoral response. Our search criteria included the keywords 'HCV,' 'Hepatitis C,' and 'vaccine' using publicly available databases. Following the screening, 54 papers were selected.Expert opinion: The investigation of novel vaccine platforms beyond traditional approaches is necessary. While progress has been made in this direction, continued investigations on the HCV virology, immunology, and vaccinology are essential to surmount associated obstacles, heling in the development of an HCV vaccine that can benefit the global public health.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"96-120"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States. 美国成年人对肺炎球菌疫苗的了解、态度和看法。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-19 DOI: 10.1080/14760584.2024.2441250

Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier

{"title":"Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States.","authors":"Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier","doi":"10.1080/14760584.2024.2441250","DOIUrl":"10.1080/14760584.2024.2441250","url":null,"abstract":"Objectives: The attitudes and perceptions of healthcare consumers (HCCs) are increasingly becoming more relevant in decision-making with healthcare providers and incorporated into healthcare decision-making by national immunization technical advisory groups and health technology assessment agencies. With newer pneumococcal vaccine options available, HCCs' attitudes and perceptions play a key role in gauging potential acceptance. The objective of this study was to assess HCCs' knowledge, attitudes, and perceptions toward pneumococcal vaccines for adults.Methods: Between March and May 2024, eligible U.S. adult HCCs were invited to participate in an online survey focusing on experiences and attitudes toward vaccines.Results: Among 141 participating HCCs, average age was 53.1 years. The majority of participants were male (51.1%) and 64.5% identified as White. Most HCCs received at least one vaccine in the past year (81.6%). HCCs most often received vaccines at medical offices and pharmacies. HCCs supported lowering the age-based pneumococcal vaccine recommendation to all adults 50 years and older and were willing to receive a supplemental pneumococcal vaccine dose following completion of the recommended series for additional protection.Conclusions: These findings indicate that new adult pneumococcal vaccines would be accepted and valued by HCCs if recommended by HCPs.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"45-52"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0